Topical sucralfate in the management of peristomal skin disease: an open study

Lyon, Calum C.; Stapleton, Mark; Smith, Amanda; Griffiths, C.E.M.; Beck, M. H.

doi:10.1046/j.1365-2230.2000.00711.x

Cited by 36 publications

(21 citation statements)

References 13 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sporadic studies and case reports available in the literature were all coherent indicating the favorable effect of topical sucralfate in wound repair and in skin protection. Topical sucralfate has been successfully studied in peristomal and perineal dermatoses, in moist desquamation during radiotherapy, in erosion and ulceration of the perineal area, in vaginal ulceration, in dystrophic epidermolysis bullosa, in second and third degree burns, and in a pilot trial with non-healing, full-thickness venous stasis ulcers refractory to 8 weeks of conventional therapy (19)(20)(21)(22)(23)(24)(25)(26)(27). The main objective of this study was to determine the effectiveness, safety and tolerability of the local treatment of chronic wounds with a sucralfate gel (SUC-LIS 95).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Topical treatment of chronic venous ulcers with sucralfate: A placebo controlled randomized study

Tumino¹,

Masuelli²,

Bei³

et al. 2008

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Venous leg ulcers are an important medical issue due to their high incidence in the elderly and the lack of a standard curative approach. Apart from surgical therapy, different medical treatments to effect ulcer wound repair and regeneration are currently being investigated. Sucralfate is a cytoprotective agent employed to prevent or treat several gastrointestinal diseases such as gastroesophageal reflux, gastritis, peptic ulcer, stress ulcer and dyspepsia. In this study we evaluated the efficacy, safety and tolerability of topical sucralfate (SUC-LIS 95) on the healing of chronic venous leg ulcers in 50 patients by a double-blind, placebo-controlled, randomized study. Our results indicated that the daily application of SUC-LIS 95 to non-infected post-phlebitis/vascular ulcers, for a median period of 42.0 days, led to complete healing in 95.6% of patients, against only 10.9% of cases with a matched placebo. A significant improvement was obtained in the SUC-LIS 95-treated patient group with regard to local tissue inflammation as well as pain and burning, and consequently, in ulcer size and the evolution of granulation tissue. Our findings were corroborated for selected patients by the morphological analysis of biopsies obtained before and after treatment. Using ultrastructural analysis we demonstrated that the topical use of SUC-LIS 95 was able to affect neoangiogenesis, increase wound contraction, promote re-epithelialization of the wound area and diminish the inflammatory reaction. Overall, our results indicated that patients with chronic venous ulcers show improvement after the use of topical sucralfate.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The sporadic studies and case reports available in the literature are all consistent, indicating the favorable effect of topical sucralfate in wound repair and in skin protection. Almost all studies indicated the safe and effective behaviour of this compound (19)(20)(21)(22)(23)(24)(25)(26)(27).…”

Section: Introductionmentioning

confidence: 99%

Topical treatment of chronic venous ulcers with sucralfate: A placebo controlled randomized study

Tumino¹,

Masuelli²,

Bei³

et al. 2008

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…Surgical treatment with stoma relocation is associated with a high chance of recurrence, but stoma closure has been associated with no recurrence . Recent studies showed promising results with newer therapies such as cultured keratinocyte autografts, topical sucralfate, topical crushed prednisone, and biologic treatment …”

Section: Preexisting Skin Diseases Account For Approximately 20% Of Pmentioning

confidence: 99%

“…55 Recent studies showed promising results with newer therapies such as cultured keratinocyte autografts, topical sucralfate, topical crushed prednisone, and biologic treatment. [56][57][58][59] Koebnerization and other skin diseases Psoriasis and vitiligo both can be seen in periostomal skin because of repeated trauma (Fig. 7).…”

Section: Fungal Infectionmentioning

confidence: 99%

Peristomal skin complications: what dermatologists need to know

2017

View full text Add to dashboard Cite

A stoma is an artificial opening to the skin formed when a part of the gastrointestinal tract is resected and opened to the skin in order to divert the bowel content to the skin surface. The incidence of stomal and peristomal complication varies from 30 to 67% with a significant negative impact on patient quality of life. Despite their prevalence, care providers tend to show insufficient awareness of peristomal skin complications, and research‐based evidence related to peristomal skin complication and management options particularly in dermatology literature is sparse. This article will present a comprehensive review of peristomal skin complications in classification, clinical presentation, causes, prevention, and management aiming at increasing knowledge about this topic.

show abstract

“…11 It has been demonstrated that sucralfate binds to basic fibroblast growth factor preventing its degradation and thereby promoting healing. 12,13 We postulated that all of these characteristics of sucralfate could be harnessed for improving healing of the hemorrhoidectomy wounds. This study was designed to examine the influence of topical sucralfate (7 percent) on postoperative pain and wound healing after MilliganMorgan's open hemorrhoidectomy through a blinded, prospective, and randomized trial.…”

mentioning

confidence: 99%